Unintended Consequences Of Broad Opioid-Sparing Claims Worries US Panel
Executive Summary
FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices.
You may also be interested in...
US FDA Faced With Suite Of Opinions Defining 'Clinically Meaningful' Opioid-Sparing Claims
Advisory committee agreed that statistically significant reduction in average opioid use and decrease in absolute amount were insufficient components on their own; a decrease in duration of use and a decrease in the amount of patients who don't need opioids received some support.
US FDA Launches Study Of Prescriber Perceptions About Abuse-Deterrent Opioids
The agency is assessing whether to use different language to describe addiction and abuse deterrence.
Opioid-Sparing Regimens Face High Hurdles After US FDA Advisory Cmte.
Panelists felt the phrase "opioid sparing" was too broad, and contended that it is difficult to develop a non-opioid alternative without an opioid as an active comparator.